iRadimed Financials - Benzinga

SPY768.33+0.54%QQQ743.25+0.72%BTC/USD84,083.74+0.54%DIA513.13+0.05%GLD381.15−0.45%TLT77.72−0.65%

iRadimed Corp

IRMDNASDAQ

Trade with Public

Trade with Public

$86.29

-0.17-0.2%

Last update: Sep 30, 11:19 AM

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Dividends Compare Options Stock Report

iRadimed Financials

iRadimed (IRMD) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
iRadimed Q2 Adj. EPS $0.46 Beats $0.42 Estimate, Sales $20.466M Beat $20.350M Estimate

Benzinga Newsdesk

PRO
iRadimed Sees Q3 Adj EPS $0.54-$0.59 vs $0.52 Est; Sees Sales $23.000M-$24.500M vs $23.650M Est

iRadimed (NASDAQ:IRMD) is looking for Q3 Adj EPS of $0.54-$0.59 vs $0.52 analyst estimate. sees sales of $23.000 million-$24.500 million vs $23.650 million analyst estimate.

Benzinga Newsdesk

PRO
iRadimed Affirms FY2026 GAAP EPS Guidance of $1.90-$2.05 vs $1.91 Est

iRadimed (NASDAQ:IRMD) affirms FY2026 GAAP EPS guidance from $1.90-$2.05 to $1.90-$2.05 vs $1.91 analyst estimate..

Benzinga Newsdesk

CORRECTION: iRadimed Raises FY2026 Adj EPS Guidance from $2.06-$2.21 to $2.09-$2.24 vs $2.08 Est; Affirms FY2026 Sales Guidance of $91.000M-$96.000M vs $91.300M Est

iRadimed (NASDAQ:IRMD) raises FY2026 Adj EPS guidance from $2.06-$2.21 to $2.09-$2.24 vs $2.08 analyst estimate. Raises FY2026 sales outlook from $91.000 million-$96.000 million to $91.000 billion-$96.000 billion vs

Benzinga News-desk

PRO
iRadimed Sees Q3 GAAP EPS $0.49-$0.54 vs $0.49 Est

iRadimed (NASDAQ:IRMD) is looking for Q3 GAAP EPS of $0.49-$0.54 vs $0.49 analyst estimate..

Benzinga Newsdesk

PRO
iRadimed Affirms FY2026 GAAP EPS Guidance of $1.90-$2.05 vs $1.91 Est

iRadimed (NASDAQ:IRMD) affirms FY2026 GAAP EPS guidance from $1.90-$2.05 to $1.90-$2.05 vs $1.91 analyst estimate..

Benzinga Newsdesk